Alembic Pharmaceuticals Limited has strengthened its footprint in the United States pharmaceutical market with the introduction of a new antibiotic product. The launch reflects the company’s ongoing strategy to expand its global portfolio and capitalize on opportunities in the highly competitive U.S. generics sector. By entering this therapeutic category, Alembic aims to enhance revenue diversification while addressing demand for cost-effective anti-infective treatments.